DDInter856 DDInter1492
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ponatinib {u} (Compound) binds {v} (Gene) RET
Ponatinib {u} (Compound) upregulates {v} (Gene) RAB15
Ponatinib {u} (Compound) downregulates {v} (Gene) ATP6V0B
Ponatinib {u} (Compound) causes {v} (Side Effect) Migraine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ponatinib (Compound) binds RET (Gene)
Ponatinib (Compound) upregulates RAB15 (Gene)
Ponatinib (Compound) downregulates ATP6V0B (Gene)
Ponatinib (Compound) causes Migraine (Side Effect)
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib may lead to a major life threatening interaction when taken with Ramucirumab
Ponatinib may lead to a major life threatening interaction when taken with Tucatinib